Archive for July 17th, 2010

Cirrosis Hepática, Ascitis- Hipertensión Portal – liver cirrhosis

Enviado por ” CONSULTORIO MÉDICO FLORES BUISSON ” MÁNCORA- PERÚ… URL: consultoriomedicofloresmancora.es.tl … El hígado, el mayor órgano del cuerpo, es esencial para mantener el organismo funcionando adecuadamente. Elimina o neutraliza venenos de la sangre, produce agentes inmunitarios para controlar las infecciones y elimina gérmenes y bacterias de la sangre. Fabrica proteínas que regulan la coagulación de la sangre y produce bilis para ayudar a absorber las grasas y las vitaminas solubles en grasa. No se puede vivir sin un hígado que funcione bien. En la cirrosis del hígado, el tejido normal y sano es reemplazado por un tejido cicatrizal que bloquea el flujo de sangre a través del órgano e impide que trabaje como debería. La cirrosis es la doceava causa de muerte por enfermedades, y mata a unas 26000 personas al año. Además, el costo de la cirrosis en términos de sufrimiento humano, costos de hospital y pérdida de productividad también es alto. Síntomas: Muchas personas con cirrosis no presentan síntomas al principio de la enfermedad. Sin embargo, a medida que el tejido cicatrizal reemplaza las células sanas, la función del hígado comienza a fallar y la persona puede tener los siguientes síntomas: Agotamiento, fatiga, falta de apetito, náusea, debilidad, pérdida de peso, dolor abdominal, vasos sanguíneos en forma de araña (angioma de araña) que se desarollan en la piel. What is Cirrhosis?: Cirrhosis is characterized anatomically by widespread nodules in the liver …

Research Roundup

Research Roundup
For the complete stories on this research, click on the title of each summary.

Read more on Yale University Office of Public Affairs

Places to Go

Places to Go
Today FINGERPRINT FRIDAY: Mrs. Zephyrhills 2005, M.J. Price, will fingerprint children as a free community service at Goin’ Postal, 38439 Fifth Ave., Zephyrhills, from 10 to 11 a.m. and at Hut no. 8, 38435 Fifth Ave., from 11 a.m. until noon.

Read more on The Pasco Tribune

Radient Pharmaceuticals Enters Into a Letter of Intent to Acquire Provista Diagnostics Inc.

Radient Pharmaceuticals Enters Into a Letter of Intent to Acquire Provista Diagnostics Inc.
TUSTIN, CA–(Marketwire – 07/13/10) – Radient Pharmaceuticals Corporation (RPC) (AMEX: RPC – News ) announced today that it has entered into a letter of intent (LOI) to acquire Provista Diagnostics Inc. (PDI), a Nevada corporation offering laboratory testing services that meet the Clinical Laboratory Improvement Act (CLIA) guidelines. Radient Pharmaceuticals intends to acquire PDI, in a stock …

Read more on Marketwire via Yahoo! Finance

KU Cancer Center eyes two scholars

KU Cancer Center eyes two scholars
The Kansas Bioscience Authority is looking to spend more than $1.6 million to bring two drug researchers to the Kansas University Cancer Center.

Read more on Lawrence Journal-World

Worldwide Market for Cancer Diagnostics, 4th Edition, The now available at ReportsandReports

Since Kalorama Information last updated our comprehensive market report on cancer testing, changes in the industry abound. Developments that were novel two years ago such as the commercialization of service products , PGx testing and tissue microarrays are showing an increased presence. Some companies who promised much in the past have not produced results. And new entrants have entered the field.
These changes and more are addressed in Kalorama Information’s Worldwide Market for Cancer Diagnostics, 4th. Edition. This report authored by Kalorama Diagnostic Analyst Shara Rosen, contains detailed market data on the following IVD segments for their use in cancer diagnostics:
• Histology/Cytology
• Immunoassays
• Flow Cytometry
• Rapid Tests
• Molecular Assays
• Tissue Arrays
• Circulating Tumor Cells
• Pharmacodiagnostics

Diagnostic tests for effective cancer screening are obviously needed more than ever. As cancer becomes more treatable, diagnostics are finding multiple expanded roles, including pharmacodiagnostics for matching the targeted treatment to the patient and ongoing disease monitoring as treatable cancer enters the realm of the chronic disease. Kalorama Information’s Worldwide Market for Cancer Diagnostics, 4th Edition represents the fourth time Kalorama has engaged in an exhaustive study on the status of this important diagnostic market. Among the market data provided in this report, readers will find:
• Immunoassay Lab Based Cancer Test Sales
• Pap Smear Testing Volumes
• World Cancer Statistics
• POC Tests
• DNA Reagents for Cancer Testing
• CTC Testing Markets
• Biochip Innovations
• New Companies with Novel Approaches
• “Laggard” Companies Who Have Not Met Expectations
• Major Protein and Molecular Markers Used in Tissue Staining
• Biomarkers Under Investigation
• Acquisitions and Mergers
• Status of PGx Testing
• Microarray Markets in Clinical Labs
• Lists of Vendors and Major Products
• Unmet Needs of the Marketplace

This report includes market analysis of the following screening tests: The Cancer Profile, CTC, Fecal Occult Blood, PSA, H. pylori, IHC, ISH As well as tests for specific cancers:
• Bladder Cancer
• Breast Cancer
• Cervical Cancer
• Colon Cancer
• Lung Cancer
• Ovarian Cancer
• Prostate Cancer

This latest edition of Kalorama Information’s study takes a fresh look at all of these developments both qualitatively and quantitatively. The report provides revenue and growth forecasts through 2014 and, as in the previous edition, analyzes the market in two ways:
• Tests for specific cancers, and
• Cancer tests in specific IVD segments
This allows the reader to match his or her own situation to the market at large.

Table OF Contents
CHAPTER ONE: Executive Summary
Introduction
Scope and Methodology
Size and Growth of the Market
Test Segments
Geographic Distribution
Market Trends
Death Rates
Revolutionary Therapeutics
Physician Factor
Consumer Lobby
Price

CHAPTER TWO: Introduction
Background
Pharmacogenomics
Test Service Commercialization
Cancer – Diagnosis and Therapy Management
Point of View

CHAPTER THREE: Market Trends In The Commercialization Of Cancer Diagnostics
Background
Demographics of Cancer, a Global Phenomenon
Cancer Testing in the World:
Screening and Government Supported Programs
United States of America
International
Europe
Mexico
China
India
Reimbursement and Commercialization of Novel Tests
Test Services – Route for Cancer Innovation
Table 3-3
Regulatory requirements of new products
Strategic Alliances and Partnerships
Personalized Medicine Advances
Gene Patents and Test Commercialization

CHAPTER FOUR: Technological Trends
Background
Biomarker Revolution
The promise of Personalized Medicine
Miniaturization and Multiplexed Biological Assays
The emergence of non-invasive tools
New Technologies Applied To Cancer Diagnostics
Overview
New Platforms
Mass Spectrometry
Chromosome Analysis
Next-Generation Sequencing
RNA – Ribonucleic Acid
The In Vitro/In Vivo Mix

CHAPTER FIVE: Market Analysis
Background
World Regional Segments of the Market for Cancer Diagnostics
Companies and Products
Has Screening Lost its Allure?
Cancer Specific Tests
Bladder Cancer
Breast Cancer
Cervical Cancer
Colon Cancer
Lung Cancer
Ovarian Cancer
Prostate Cancer

CHAPTER SIX: Cancer Tests in IVD Segments (Segment Analysis)
Cancer Diagnostics and IVD Markets
The Market For Cancer Tests In Clinical Chemistry
The Market For Immunoassay Cancer Tests, Lab & Rapid
Point-of-care
The Market for Cancer Tests in Histology / Cytology
Traditional Tissue Stains
Pap Smear and HPV Testing
IHC/ISH
The Market for Tissue Microarrays
The Market For Cancer Tests in Flow Cytometry
The Market for Circulating Tumor Cells in Cancer Diagnostics
The Market For Cancer Molecular Assays
The Market For Cancer Tests in Pharmacodiagnostics
The market for Biochips and Arrays in Cancer Diagnostics
The Commercial Outlook for Cancer Diagnostics

CHAPTER SEVEN: Conclusions
Conclusions and Strategic Implications
Conclusion 1
Implication:
Conclusion 2
Implication:
Conclusion 4
Implication
Conclusion 5
Implication:
Conclusion 6:
Unmet Market Needs
Unmet Need #1
Unmet Need #2
Unmet Need #3

CHAPTER EIGHT: The Top Tier of IVD Companies and their investment in cancer diagnostics
Abbott Diagnostics
Molecular Histology
Molecular Diagnostics
Immunoassays
Beckman Coulter Inc
FOB
Flow Cytometry
Becton, Dickinson and Company (BD)
Histology
bioMerieux Inc
Bio-Rad Laboratories Inc
Dako A/S
Fujirebio Diagnostics, Inc
Gen-Probe Inc
Hologic, Inc
Histology
HPV
Inverness Medical Innovations
Ortho Clinical Diagnostics
QIAGEN N.V
Roche Diagnostics Indianapolis, IN www.roche.com Recent Revenue History ($ million)
Histology
Immunoassays
PCR
Research
Siemens Medical Solutions Diagnostics
Molecular
In Vivo
Sysmex Corporation

CHAPTER NINE: The Status Quo in Cancer Diagnostics
AdnaGen AG
Agendia BV
AMDL Diagnostics, Inc. (ADI)
American Diagnostica Inc
Aperio Technologies, Inc
Asuragen, Inc
AviaraDx
Binding Site (The) Ltd
BioCurex Inc
BioGenex Laboratories, Inc
BioImagene
Bio-Reference Laboratories, Inc
Biotage AB
bioTheranostics
BioView Ltd
Celera Diagnostics
China Medical Technologies, Inc
Cisbio Bioassays
Clarient Inc. (formerly ChromaVision)
Clinical Data, Inc
CytoCore, Inc
DxS Ltd
Epigenomics AG
Genetix Applied Imaging
Genomic Health, Inc
Genzyme Genetics
Health Discovery Corporation
HistoRx, Inc
Ikonisys, Inc
InterGenetics Inc
Ipsogen SA
Lab21 Healthcare
Laboratory Corporation of America Holdings (LabCorp)
Life Technologies
Monogram Biosciences, Inc
mtm laboratories AG
Myriad Genetics, Inc
Nanosphere, Inc
OncoVista Innovative Therapies, Inc
Pathwork Diagnostics
Precision Therapeutics
Prometheus Laboratories Inc
Quest Diagnostics
Response Genetics, Inc
Rosetta Genomics Ltd
Sequenom
Transgenomic Inc
Veridex, LLC
Vermillion Inc
Zila, Inc

CHAPTER TEN: New Entrants And Novel Product Developers
20/20 GeneSystems, Inc
454 Life Sciences Corporation
Acrometrix Corporation (Life Tech.)
Acupath Laboratories, Inc
Advalytix
Affymetrix, Inc
Allegro Diagnostics
Althea Technologies, Inc
Amorfix Life Sciences Ltd
Arbor Vita Corporation
ArcticDx Inc
Arrayit Diagnostics Inc
AVEO Pharmaceuticals, Inc
Axela, Inc
Baypoint Biosystems, Inc
Biodesix, Inc
Biologix Diagnostics, LLC
BioMarker Strategies, LLC
Biomoda
BioMosaics
BioProspecting NB, Inc. (BPNBI)
BioServe
Biosystems International SAS (BSI)
BioTrove, Inc
Cambridge Research & Instrumentation, Inc. (CRi)
Cangen Biotechnologies, Inc
Caris Diagnostics
Castle Biosciences Inc
Celerus Diagnostics
Cell Biosciences
CeMines, Inc
Cepheid
ChromoCure Inc
Chronix Biomedical Inc
Clinical Genomics Pty Ltd
CombiMatrix Molecular Diagnostics (CMDX)
Comprehensive Cancer Cell (CCC) Diagnostics Inc
Compugen Ltd
Correlogic Systems, Inc
CS-Keys, Inc
deCode Genetics Inc. —
DiaGenic ASA
DiagnoCure –
Diagnoplex
Diagnostic Biosystems Company
DNA Direct, Inc
DexTerity Diagnostics
EDP Biotech Corporation
Epistem Plc
Exact Sciences Corp
Exiqon A/S
ExonHit Therapeutics
Exosome Diagnostics Inc
Expression Pathology Inc
Falcon Genomics, Inc
FASgen Diagnostics, LLC
Fluxion Biosciences
Foligo Therapeutics, Inc
Gastrocor
Genelex Corporation
GeneNews Limited
Genoptix
iKaryos Diagnostics
Illumina
Inostics GmbH
InteRNA Technologies B.V
Intrinsic Bioprobes Inc
Invirion Diagnostics, LLC
InVivoScribe Technologies
Iris BioTechnologies Inc
IRIS International, Inc
MabCure Inc
MacroArray Technologies, LLC
MagArray Inc
Martell Biosystems, Inc
Med BioGene, Inc. (MBI)
Medical Prognosis Institute
Metabolon, Inc
Miraculins Inc
MolecularMD Corp
Neogenix Oncology, Inc
NextGen Sciences
Nuvera Biosciences
Olink AB
Oncimmune LLC
OncoMethylome Sciences S.A
On-Q-ity
Orion Genomics
Oxford BioTherapeutics
Pacific Edge Biotechnology Ltd. (PEB)
Photocure ASA
Power3 Medical Products, Inc
Prediction Sciences
Predictive Biosciences
PrognosDx Health, Inc
Provista Life Sciences LLC
Rubicon Genomics, Inc
Rules-Based Medicine, Inc. (RBM)
Saladax Biomedical, Inc. (SBI)
SensiGen LLC
Sienna Cancer Diagnostics
Signature Genomic Laboratories, LLC
Singulex Inc
Skyline Diagnostics B.V
Source MDx
Soar BioDynamics, Ltd
Strategic Diagnostics Inc
Synergenz Bioscience Ltd
Targeted Molecular Diagnostics (TMD)
Theranostics Health (TH)
TrimGen Corporation
TrovaGene, Inc
Vitatex Inc
WaferGen Biosystems, Inc
Xceed Molecular (formerly MetriGenix Corporation)
Zetiq Technologies Ltd

When I Grow Up (Hawaii) – Kaiser Permanente Thrive Ad

Kaiser Permanente women in Hawaii lead the nation in breast cancer screening, according to The National Committee on Quality Assurance’s Quality Compass® report for 2009. “When I Grow Up, first launched in 2008, promotes proactive preventive measures for staying healthy. Kaiser Permanente women get mammograms. Have you had yours?

Breast Enhancement Surgery: Understand the Risks

Working with a qualified plastic surgeon and following all of the instructions will ensure minimal complications associated with the breast enhancement surgery. But, even if your plastic surgeon is careful, there may still be risks, complications and other effects. What are the risks associated with breast enhancement surgery?

Many women undergo bust procedures each year to enhance the size of their busts. Most surgeries are successful, however some can produce complications. Before you decide on breast augmentation surgery, you should understand the risks so that you can make an informed decision. Your plastic surgeon should discuss with you all of the risks prior to the surgery. Some of the potential complications that the doctor may talk to you about are some unusual occurrences of adverse reactions to anesthesia. Blood accumulation may need to be drained surgically to avoid infection. Although rare, an infection that does not subside with appropriate treatment may require temporary removal of the implant. Changes in nipple or sensation on busts may result from breast enhancement surgery, although they usually are temporary.

When an implant is inserted, a scar capsule forms around it as part of the natural healing process. The capsule may sometimes tighten and compress the implant, causing the bust to feel firmer than normal. Capsular contracture can occur to varying degrees. If it is severe, it can cause discomfort or changes in the bust appearance. In such cases, further surgery may be needed to modify or remove the scar tissue, or perhaps remove or replace the implant.

Breast implants do not last forever, they need to be replaced. Gravity and aging can alter the size and shape your busts. Many individuals may choose to undergo breast lifting to minimize signs of aging reflecting on their physical appearance. Sometimes ruptures are rare phenomena which can only occur as a result of trauma to the chest. If a saline-filled implant breaks, it is absorbed by the body within hours. The size of your bust will definitely change and surgery may be necessary to replace the implant. If a silicone implant breaks, it could cause harm to your body. Many implants come with a lifespan or a guarantee period of 10 to 12 years (depending on the type) after which replacement is required. In case of unusual rupture or leakage of defective implants within the time frame mentioned, manufacturers offer product replacement and defray some surgical fees.

To detect ruptures or abnormalities, women need to undergo mammography examinations, ultrasound, or magnetic resonance imaging periodically. Women should also perform self breast examinations. You should select a professional radiology technician who is used to taking x-rays of enhanced busts. Remember that it is quite possible if x-ray is not performed by a skilled technician in which case the breast cancer remains undiagnosed due to breast implants. After your implant surgery, remember to consult and follow your plastic surgeons instructions strictly. Your doctor will want to meet with you periodically to evaluate your progress. Your doctor should be available for any questions that you may have after surgery.

Before undergoing any breast enhancement surgery, make sure that research is done. Understand all the risks associated with the process that may or may not occur during and after the surgery. Set realistic expectations from the process and realize that effects of the procedure will not last forever. Continual proper care is required to maintain the appearance.

Terramed Alliance News Healthy Diet Can?t Hurt, May Help Breast Cancer Patients

Breast cancer is the second leading cause of cancer death in women in the United States, with approximately 180,000 cases diagnosed each year. Researchers continue to evaluate environmental factors, such as diet, that influence the development of breast cancer. Numerous studies have provided a wealth of often-contradictory information about the detrimental and protective factors of different foods. High fruit and vegetable consumption has been associated with a reduced risk for developing at least 10 different cancers. Studies evaluating the influence of diet on breast cancer prognosis have produced inconsistent results.

Researchers from California and Utah assessed a cohort of 1,901 women from the Life After Cancer Epidemiology (LACE) Study who were diagnosed with early-stage breast cancer between 1997 and 2000. Upon entering the study, the women completed a food frequency questionnaire (FFQ). The researchers used the data from the FFQs to identify two dietary patterns among the women: a prudent diet included high intakes of fruits, vegetables, whole grains, and poultry, whereas a Western diet included high intakes of red and processed meats and refined grains. The researchers then evaluated the rates of recurrence, overall death, death from breast cancer, and death from causes other than breast cancer. As of May 2008, there were 268 breast cancer recurrences and 226 deaths, 128 of which were attributed to breast cancer.

After analyzing the data, the researchers found that women who followed the prudent diet had a statistically significant decreased risk of overall death and death from non–breast cancer causes, whereas those who followed the Western diet had an increased risk of overall death and death from non–breast cancer causes. Neither dietary pattern was associated with a risk of breast cancer recurrence or death from breast cancer. Because the prudent diet was associated with a decreased risk of overall death, the researchers concluded that “women diagnosed with early-stage breast cancer may benefit from dietary patterns that include healthier foods such as fruits, vegetables, whole grains, and poultry and less consumption of red meat and refined foods.” Journal of Clinical Oncology

Terramed Alliance is a non-profit charity organization dedicated to research, education and advocacy of breast cancer. One of the vision of Terramed Alliance is to provide this community and Internet users with a charity based research and education entity. Advocacy of breast cancer through education is vital to the reduction of this disease.  For any requests and enquiries, please contact at us: cancer@terramedalliance.us www.terramedalliance.us

Cartagena sees final as win-win situation

Cartagena sees final as win-win situation
ASSOCIATED PRESS

Read more on Lubbock Avalanche-Journal